Cargando…
COT-11 Administration of Bevacizumab for patients who failed to complete Stupp regimen after glioblastoma surgery
Stupp regimen is widely used as the standard treatment after glioblastoma surgery, but in some cases treatment must be discontinued for various reasons. We experienced Bevacizumab in two patients who were unable to continue treatment in the Stupp regimen, and report our experience with literature re...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699073/ http://dx.doi.org/10.1093/noajnl/vdaa143.097 |
_version_ | 1783615965260414976 |
---|---|
author | Kon, Takashi Imaizumi, Yoichi Kobayashi, Yusuke Sato, Yosuke Shimizu, Katsuyoshi Mizutani, Tohru |
author_facet | Kon, Takashi Imaizumi, Yoichi Kobayashi, Yusuke Sato, Yosuke Shimizu, Katsuyoshi Mizutani, Tohru |
author_sort | Kon, Takashi |
collection | PubMed |
description | Stupp regimen is widely used as the standard treatment after glioblastoma surgery, but in some cases treatment must be discontinued for various reasons. We experienced Bevacizumab in two patients who were unable to continue treatment in the Stupp regimen, and report our experience with literature review. First patient is a man in his 60s. Resection of glioblastoma of the left cerebral hemisphere was performed, and postoperatively right hemiparesis and aphasia remained. Irradiation and administration of Temozolomide were performed, but Temozolomide was unable to continue because of side effects. After systemic management, Bevacizumab was administered, and reduction of residual tumor and peripheral edema were observed, and the patient began to speak. After 12 cycles of administration, the tumor regrew, and he died. Second patient is a woman in her 80s. Craniotomy was performed for hemorrhagic infarction of the left cerebral hemisphere, postoperatively, aphasia, right hemiparesis remained, bedridden, and was unable to eat. Four months after initial surgery, a tumor was found in left parietal lobe and was resected. The pathological diagnosis was glioblastoma. For the treatment of recurrence, the patient was unable to be transferred for radiochemotherapy, so the patient was treated with Temozolomide and Bevacizumab. The patient’s condition became better, eat by herself, and could play in rehabilitation facility on the wheelchair. After 12 cycles of bevacizumab, the tumor subsequently enlarged, and died. Although the effect is limited, there are some cases in which Bevacizumab administration could maintain patient’s condition by controlling tumor growth for a certain period of time. From the experience of these patients, it seems that even in patients with postoperative poor Karnofsky Performance Status (KPS)and elderly people, Bevacizumab administration would be an option before transitioning to end-of-life care. |
format | Online Article Text |
id | pubmed-7699073 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-76990732020-12-02 COT-11 Administration of Bevacizumab for patients who failed to complete Stupp regimen after glioblastoma surgery Kon, Takashi Imaizumi, Yoichi Kobayashi, Yusuke Sato, Yosuke Shimizu, Katsuyoshi Mizutani, Tohru Neurooncol Adv Supplement Abstracts Stupp regimen is widely used as the standard treatment after glioblastoma surgery, but in some cases treatment must be discontinued for various reasons. We experienced Bevacizumab in two patients who were unable to continue treatment in the Stupp regimen, and report our experience with literature review. First patient is a man in his 60s. Resection of glioblastoma of the left cerebral hemisphere was performed, and postoperatively right hemiparesis and aphasia remained. Irradiation and administration of Temozolomide were performed, but Temozolomide was unable to continue because of side effects. After systemic management, Bevacizumab was administered, and reduction of residual tumor and peripheral edema were observed, and the patient began to speak. After 12 cycles of administration, the tumor regrew, and he died. Second patient is a woman in her 80s. Craniotomy was performed for hemorrhagic infarction of the left cerebral hemisphere, postoperatively, aphasia, right hemiparesis remained, bedridden, and was unable to eat. Four months after initial surgery, a tumor was found in left parietal lobe and was resected. The pathological diagnosis was glioblastoma. For the treatment of recurrence, the patient was unable to be transferred for radiochemotherapy, so the patient was treated with Temozolomide and Bevacizumab. The patient’s condition became better, eat by herself, and could play in rehabilitation facility on the wheelchair. After 12 cycles of bevacizumab, the tumor subsequently enlarged, and died. Although the effect is limited, there are some cases in which Bevacizumab administration could maintain patient’s condition by controlling tumor growth for a certain period of time. From the experience of these patients, it seems that even in patients with postoperative poor Karnofsky Performance Status (KPS)and elderly people, Bevacizumab administration would be an option before transitioning to end-of-life care. Oxford University Press 2020-11-28 /pmc/articles/PMC7699073/ http://dx.doi.org/10.1093/noajnl/vdaa143.097 Text en © The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Supplement Abstracts Kon, Takashi Imaizumi, Yoichi Kobayashi, Yusuke Sato, Yosuke Shimizu, Katsuyoshi Mizutani, Tohru COT-11 Administration of Bevacizumab for patients who failed to complete Stupp regimen after glioblastoma surgery |
title | COT-11 Administration of Bevacizumab for patients who failed to complete Stupp regimen after glioblastoma surgery |
title_full | COT-11 Administration of Bevacizumab for patients who failed to complete Stupp regimen after glioblastoma surgery |
title_fullStr | COT-11 Administration of Bevacizumab for patients who failed to complete Stupp regimen after glioblastoma surgery |
title_full_unstemmed | COT-11 Administration of Bevacizumab for patients who failed to complete Stupp regimen after glioblastoma surgery |
title_short | COT-11 Administration of Bevacizumab for patients who failed to complete Stupp regimen after glioblastoma surgery |
title_sort | cot-11 administration of bevacizumab for patients who failed to complete stupp regimen after glioblastoma surgery |
topic | Supplement Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699073/ http://dx.doi.org/10.1093/noajnl/vdaa143.097 |
work_keys_str_mv | AT kontakashi cot11administrationofbevacizumabforpatientswhofailedtocompletestuppregimenafterglioblastomasurgery AT imaizumiyoichi cot11administrationofbevacizumabforpatientswhofailedtocompletestuppregimenafterglioblastomasurgery AT kobayashiyusuke cot11administrationofbevacizumabforpatientswhofailedtocompletestuppregimenafterglioblastomasurgery AT satoyosuke cot11administrationofbevacizumabforpatientswhofailedtocompletestuppregimenafterglioblastomasurgery AT shimizukatsuyoshi cot11administrationofbevacizumabforpatientswhofailedtocompletestuppregimenafterglioblastomasurgery AT mizutanitohru cot11administrationofbevacizumabforpatientswhofailedtocompletestuppregimenafterglioblastomasurgery |